13,366 Shares in Supernus Pharmaceuticals, Inc. $SUPN Purchased by GSA Capital Partners LLP

Posted by Stanley Muller on Aug 21st, 2026

GSA Capital Partners LLP purchased a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the second quarter, HoldingsChannel reports. The institutional investor purchased 13,366 shares of the specialty pharmaceutical company’s stock, valued at approximately $622,000.

Other institutional investors also recently added to or reduced their stakes in the company. State Street Corp grew its stake in shares of Supernus Pharmaceuticals by 1.4% in the 4th quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock valued at $110,296,000 after purchasing an additional 31,668 shares during the period. Geode Capital Management LLC lifted its position in shares of Supernus Pharmaceuticals by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company’s stock worth $73,215,000 after buying an additional 62,875 shares during the period. Loomis Sayles & Co. L P lifted its position in shares of Supernus Pharmaceuticals by 12.7% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company’s stock worth $72,007,000 after buying an additional 162,905 shares during the period. Stephens Investment Management Group LLC boosted its stake in Supernus Pharmaceuticals by 4.5% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock valued at $69,904,000 after buying an additional 61,120 shares in the last quarter. Finally, Woodline Partners LP boosted its stake in Supernus Pharmaceuticals by 63.5% in the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after buying an additional 490,835 shares in the last quarter.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $47.45 on Friday. The business has a fifty day moving average price of $46.72 and a 200 day moving average price of $48.85. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $42.45 and a fifty-two week high of $59.68. The stock has a market capitalization of $2.76 billion, a price-to-earnings ratio of -24.71, a P/E/G ratio of 0.89 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($1.43). The company had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The firm’s quarterly revenue was up 32.4% on a year-over-year basis. During the same quarter last year, the company earned $0.40 EPS. On average, equities analysts expect that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Cantor Fitzgerald upped their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Zacks Research raised Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 6th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Finally, Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $62.83.

View Our Latest Research Report on Supernus Pharmaceuticals

Supernus Pharmaceuticals Company Profile

(Free Report)

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.